stockrow
Saturday 7 November 2026
Export RARE’s income statement to Excel — free account
Ultragenyx Pharmaceutical Inc.
RARE Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $673.0 million, up 20.2% from fiscal 2024.
- Revenue
- +8.13%
- EPS
- +36.2%
- Free cash flow
- +12.5%
Quarter to September 2026, against a year earlier
15.43
0.14
−0.90%
Follow RARE
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.37 | 3.15 | 4.75 | 2.10 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(22.68) | (10.70) | (35.08) | (35.69) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.36 | 2.53 | 4.34 | 1.74 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.41) | (3.41) | (6.41) | (2.90) | |
EV/FCF |
(3.26) | (3.34) | (6.30) | (2.84) | |
Quick Ratio |
2.18 | 1.64 | 1.40 | 1.11 | |
Current Ratio |
2.48 | 2.02 | 1.73 | 1.40 | |
Net Debt/EBITDA |
6.54 | 2.55 | 4.36 | 2.63 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.44 | 0.51 | 0.56 | 0.61 | |
Operating CF/Net income |
0.78 | 1.06 | 1.05 | 0.36 | |
Capex/Depreciation |
(0.11) | (0.86) | (0.12) | (0.22) | |
Interest Coverage |
(5.65) | (8.05) | (3.41) | (5.50) | |
Research and Development Expense of Revenue |
98.07% | 137.50% | 78.04% | 89.02% | |
Selling, General and Administrative Expense of Revenue |
42.51% | 64.71% | 41.12% | 56.07% | |
Intangible Assets out of Total Assets |
0.14 | 0.17 | 0.17 | 0.18 | |
Share Based Compensation of Revenue |
17.87% | 22.06% | 15.89% | 19.65% | |
Graham Net Nets |
(0.29) | (0.42) | (0.28) | (0.66) | |
Graham Number |
10.33 | 17.96 | 19.37 | 20.73 | |
Earnings Yield |
(25.39%) | (29.16%) | (17.49%) | (34.50%) | |
Free Cash Flow Yield |
(21.47%) | (24.10%) | (14.52%) | (29.13%) | |
Revenue per Share |
2.10 | 1.35 | 2.10 | 1.69 | |
Operating CF per Share |
(1.01) | (1.96) | (0.95) | (0.42) | |
Capex per Share |
(0.01) | (0.06) | (0.01) | (0.02) | |
Free Cash Flow per Share |
(1.02) | (2.02) | (0.96) | (0.44) | |
Cash per Share |
6.90 | 4.11 | 2.87 | 2.61 | |
Shareholders Equity per Share |
(0.81) | (2.35) | (2.86) | (3.68) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.81) | (2.35) | (2.86) | (3.68) | |
Free Cash Flow |
(101.00) | (203.00) | (98.00) | (45.00) | |
Working Capital |
567.00 | 332.00 | 255.00 | 155.00 | |
Capital Expenditures |
(1.00) | (6.00) | (1.00) | (2.00) | |
Net Current Asset Value |
(661.00) | (875.00) | (949.00) | (1,019.00) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.04 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
140.00 | 109.92 | 162.23 | 139.27 | |
Average Payables |
35.00 | 44.73 | 36.62 | 42.79 | |
Average Inventory |
48.50 | 50.52 | 52.75 | 55.60 | |
Average Assets |
1,517.50 | 1,303.96 | 1,285.13 | 1,188.72 | |
Average Common Equity |
87.50 | (45.88) | (69.86) | (183.42) |
Columns are period end dates · fundamentals updated 6 Nov 2026